InflaRx (NASDAQ:IFRX) Stock Price Expected to Rise, Guggenheim Analyst Says

InflaRx (NASDAQ:IFRX) had its target price raised by Guggenheim from $7.00 to $10.00 in a research note published on Wednesday, Marketbeat reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of InflaRx in a report on Friday, March 21st.

InflaRx Price Performance

Shares of IFRX stock opened at $1.15 on Wednesday. The company has a market capitalization of $77.20 million, a PE ratio of -1.06 and a beta of 1.98. The firm’s 50-day moving average is $1.80 and its two-hundred day moving average is $1.89. InflaRx has a 12 month low of $1.13 and a 12 month high of $2.82.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. Sell-side analysts forecast that InflaRx will post -1.04 EPS for the current year.

Hedge Funds Weigh In On InflaRx

Several large investors have recently made changes to their positions in the stock. Two Sigma Securities LLC acquired a new stake in InflaRx in the 4th quarter valued at approximately $28,000. Geode Capital Management LLC boosted its position in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock worth $119,000 after buying an additional 11,900 shares during the period. Commonwealth Equity Services LLC grew its stake in shares of InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after buying an additional 19,000 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of InflaRx in the fourth quarter valued at $51,000. Finally, Cubist Systematic Strategies LLC acquired a new position in InflaRx during the 4th quarter worth about $55,000. 42.39% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.